79 results on '"Resch, G."'
Search Results
2. Genotypes of Staphylococcus aureus: On-farm epidemiology and the consequences for prevention of intramammary infections
- Author
-
Leuenberger, A., Sartori, C., Boss, R., Resch, G., Oechslin, F., Steiner, A., Moreillon, P., and Graber, H.U.
- Published
- 2019
- Full Text
- View/download PDF
3. On-Chip Nanotweezers for Ultrafast Antibacterial Susceptibility Testing at the Single-Cell Scale: The Case of Bacteriophages
- Author
-
Tartari, E., primary, Glicenstein, S., additional, Villa, N., additional, Picard, E., additional, Hadji, E., additional, Marcoux, P.R., additional, Zelsmann, M., additional, Resch, G., additional, and Houdré, R., additional
- Published
- 2023
- Full Text
- View/download PDF
4. On-Chip Optical Nanotweezers for Phage Trapping and Identification
- Author
-
Glicenstein, S., primary, Villa, N., additional, Tartari, E., additional, Picard, E., additional, Marcoux, P. R., additional, Zelsmann, M., additional, Resch, G., additional, Houdré, R., additional, and Hadji, E., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Efficacy assessment of a novel endolysin PlyAZ3aT for the treatment of ceftriaxone-resistant pneumococcal meningitis in an infant rat model
- Author
-
Valente, L.G., Le, N.D., Pitton, M., Chiffi, G., Grandgirard, D., Jakob, S.M., Cameron, D.R., Resch, G., Que, Y.A., and Leib, S.L.
- Subjects
Random Allocation ,Streptococcus pneumoniae ,Meningitis, Pneumococcal ,Vancomycin ,Ceftriaxone ,Endopeptidases ,Animals ,Anti-Bacterial Agents/pharmacology ,Anti-Bacterial Agents/therapeutic use ,Ceftriaxone/pharmacology ,Ceftriaxone/therapeutic use ,Meningitis, Pneumococcal/microbiology ,Rats ,Rats, Wistar ,Vancomycin/pharmacology ,Anti-Bacterial Agents - Abstract
Treatment failure in pneumococcal meningitis due to antibiotic resistance is an increasing clinical challenge and alternatives to antibiotics warrant investigation. Phage-derived endolysins efficiently kill gram-positive bacteria including multi-drug resistant strains, making them attractive therapeutic candidates. The current study assessed the therapeutic potential of the novel endolysin PlyAZ3aT in an infant rat model of ceftriaxone-resistant pneumococcal meningitis. Efficacy of PlyAZ3aT was assessed in a randomized, blinded and controlled experimental study in infant Wistar rats. Meningitis was induced by intracisternal infection with 5 x 107 CFU/ml of a ceftriaxone-resistant clinical strain of S. pneumoniae, serotype 19A. Seventeen hours post infection (hpi), animals were randomized into 3 treatment groups and received either (i) placebo (phosphate buffered saline [PBS], n = 8), (ii) 50 mg/kg vancomycin (n = 10) or (iii) 400 mg/kg PlyAZ3aT (n = 8) via intraperitoneal injection. Treatments were repeated after 12 h. Survival at 42 hpi was the primary outcome; bacterial loads in cerebrospinal fluid (CSF) and blood were secondary outcomes. Additionally, pharmacokinetics of PlyAZ3aT in serum and CSF was assessed. PlyAZ3aT did not improve survival compared to PBS, while survival for vancomycin treated animals was 70% which is a significant improvement when compared to PBS or PlyAZ3aT (p
- Published
- 2022
6. Fast phage susceptibility testing and infectious titer measurement through lensless imaging
- Author
-
Perlemoine, P., Marcoux, P., Picard, E., Hadji, E., Zelsmann, M., Mugnier, G., Marchet, A., Resch, G., Lacot, E., Clot, Marielle, Laboratoire des technologies de la microélectronique (LTM ), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)
- Subjects
[PHYS]Physics [physics] ,ComputingMilieux_MISCELLANEOUS ,[PHYS] Physics [physics] - Abstract
International audience
- Published
- 2022
7. UVC inactivation of pathogenic samples suitable for cryoEM analysis
- Author
-
Depelteau, J. S., Renault, L., Althof, N., Cassidy, C. K., Mendonça, L. M., Jensen, G. J., Resch, G. P., Briegel, A., Depelteau, J. S., Renault, L., Althof, N., Cassidy, C. K., Mendonça, L. M., Jensen, G. J., Resch, G. P., and Briegel, A.
- Abstract
Cryo-electron microscopy has become an essential tool to understand structure and function of biological samples, from individual proteins to whole cells. Especially for pathogens, such as disease-causing bacteria and viruses, insights gained by cryo-EM can aid in developing cures. However, due to the biosafety restrictions of human pathogens, samples are often treated by chemical fixation to render the pathogen inert, affecting the delicate ultrastructure of the sample. Alternatively, researchers use in vitro or ex vivo models, which are non-pathogenic but lack the complexity of the pathogen of interest. Here we show that ultraviolet-C (UVC) radiation at cryogenic temperatures can be used to eliminate or dramatically reduce the infectivity of two model organisms, a pathogenic bacterium (Vibrio cholerae) and a virus-like particle (the ICP1 bacteriophage). We show no discernable structural impact of this treatment of either sample using two cryo-EM methods: cryo-electron tomography (cryo-ET) followed by sub-tomogram averaging (STA), and single particle analysis (SPA). Additionally, we applied the UVC irradiation to the protein apoferritin (ApoF), which is a widely used test sample for high resolution SPA studies. The UVC-treated ApoF sample resulted in a 2.1 Å structure that did not reveal any discernable structural damage. Together, these results show that the UVC irradiation dose that effectively inactivates cryo-EM samples does not negatively impact their structure. This research demonstrates that UVC treatment is an effective and inexpensive addition to the cryo-EM sample preparation toolbox.
- Published
- 2021
8. Database. Market uptake of concentrating solar power in Europe: model-based analysis of drivers and policy trade-offs. Deliverable 8.3 MUSTEC project
- Author
-
Resch, G., Schöniger, F., Kleinschmitt, C., Franke, K., Sensfuß, F., Thonig, R., and Lilliestam, J.
- Abstract
This document describes the data underlying the modelling works for Deliverable 8.2 Market uptake of concentrating solar power in Europe: model-based analysis of drivers and policy trade-offs (Resch et al., 2020). They were conducted using the Green-X model (TU Wien) and the Enertile model (Fraunhofer ISI). Sufficiently high climate ambitions are another enabler of CSP development, because they hinder the use of fossil power plants as a backup of fluctuating renewables and supply of electricity demand exceeding the realizable potential of other renewables. Hence, CSP with its additional advantage of dispatchability becomes more important under such conditions.
- Published
- 2020
9. Market uptake of concentrating solar power in Europe. Model-based analysis of drivers and policy trade-offs. Deliverable 8.2 of the Horizon2020 project MUSTEC
- Author
-
Resch, G., Schöniger, F., Kleinschmitt, C., Franke, K., Sensfuß, F., Thonig, R., and Lilliestam, J.
- Abstract
We conducted a model-based analysis evaluating the role of CSP in the EU electricity system up to 2050. In particular, we analysed how cooperation, sector coupling, electricity demand levels, underlying RES policy concepts and pathways, and infrastructural developments/prerequisites impact the market uptake of CSP in the EU. Our results show, that cooperation among European countries leads to higher expansions of CSP power plants than the pathway following national preferences. Sufficiently high climate ambitions are another enabler of CSP development, because they hinder the use of fossil power plants as a backup of fluctuating renewables and supply of electricity demand exceeding the realizable potential of other renewables. Hence, CSP with its additional advantage of dispatchability becomes more important under such conditions.
- Published
- 2020
10. Pivotal decisions and key factors for robust CSP strategies. Deliverable 7.4 MUSTEC project
- Author
-
Schöniger, F., Resch, G., Kleinschmitt, C., Franke, K., Sensfuß, F., Lilliestam, J., and Thonig, R.
- Abstract
Concentrating Solar Power (CSP) offers flexible and decarbonised power generation and is - as a solar power-based balancing opportunity – able to contribute to the transition towards sustainable and stable future electricity systems. To have this technology available for the generation portfolio in Europe when it will be needed, certain conditions in the electricity systems have to be met. In this report, we shed a light on key factors and pivotal decisions for successful CSP deployment in Europe. From the wide range of factors that are relevant for CSP deployment in Europe’s future electricity system, we elaborate in particular on the effect of cooperation, demand-side management, electricity grid expansion, decarbonisation ambition, technology cost developments of CSP and competing technologies, sector coupling, and increasing shares of fluctuating renewables and nuclear phase-out on CSP deployment. This assessment condenses many different outcomes of the MUSTEC project so far and is based on the policy pathway elaboration (WP7) and the core findings from the integrated model-based assessment (WP8). Compiled from these MUSTEC research activities, we present in this report the key drivers and policy decisions that are needed for effective CSP deployment in Europe in the coming years up to 2050.
- Published
- 2020
11. ePS6.07 Evaluation of the activity of lytic bacteriophages on a representative collection of Pseudomonas aeruginosa clinical isolates collected from adult patients with cystic fibrosis
- Author
-
Save, J., primary, Sauty, A., additional, Prella, M., additional, Koutsokera, A., additional, and Resch, G., additional
- Published
- 2020
- Full Text
- View/download PDF
12. Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains
- Author
-
Rohde, C., Resch, G., Pirnay, J.P., Blasdel, B.G., Debarbieux, L., Gelman, D., Górski, A., Hazan, R., Huys, I., Kakabadze, E., Łobocka, M., Maestri, A., Almeida, GMF, Makalatia, K., Malik, D.J., Mašlaňová, I., Merabishvili, M., Pantucek, R., Rose, T., Štveráková, D., Van Raemdonck, H., Verbeken, G., and Chanishvili, N.
- Subjects
viruses ,Bacteriophage ,adaptation ,phage therapy ,production ,prophage ,regulation ,resistance - Abstract
Phage therapy is increasingly put forward as a "new" potential tool in the fight against antibiotic resistant infections. During the "Centennial Celebration of Bacteriophage Research" conference in Tbilisi, Georgia on 26-29 June 2017, an international group of phage researchers committed to elaborate an expert opinion on three contentious phage therapy related issues that are hampering clinical progress in the field of phage therapy. This paper explores and discusses bacterial phage resistance, phage training and the presence of prophages in bacterial production strains while reviewing relevant research findings and experiences. Our purpose is to inform phage therapy stakeholders such as policy makers, officials of the competent authorities for medicines, phage researchers and phage producers, and members of the pharmaceutical industry. This brief also points out potential avenues for future phage therapy research and development as it specifically addresses those overarching questions that currently call for attention whenever phages go into purification processes for application.
- Published
- 2018
13. South East Europe Electricity Roadmap (SEERMAP)
- Author
-
Szabo, L., primary, Mezosi, A., additional, Pato, Zs., additional, Kacsor, E., additional, Kelemen, A., additional, Resch, G., additional, and Liebmann, L., additional
- Published
- 2018
- Full Text
- View/download PDF
14. A techno-economic analysis of EU renewable electricity policy pathways in 2030
- Author
-
del Río, P., Resch, G., Ortner, A., Liebmann, L., Busch, S., Panzer, C., del Río, P., Resch, G., Ortner, A., Liebmann, L., Busch, S., and Panzer, C.
- Abstract
The aim of this paper is to assess several pathways of a harmonised European policy framework for supporting renewable electricity (RES-E) in a 2030 horizon according to different criteria. The pathways combine two main dimensions: degrees of harmonisation and instruments and design elements. A quantitative model-based analysis with the Green-X model is provided. The results of the simulations show that there are small differences between the evaluated cases regarding effectiveness. All the policy pathways score similarly with respect to RES-E deployment, i.e., with different degrees of harmonisation and whether using a feed-in tariff, a feed-in premium, a quota system with banding or a quota without banding scheme. In contrast, the policy costs clearly differ across the pathways, but the differences can mostly be attributed to the instruments rather than to the degrees of harmonisation. This is also the case with other criteria (static and dynamic efficiency and the socioeconomic and environmental benefits in terms of CO2 emissions and fossil fuels avoided). Both the degree of harmonisation and the choice of instrument influence the distribution of support costs across countries. Finally, our findings suggest that keeping strengthened national support leads to similar results to other policy pathways.
- Published
- 2017
15. Policy Dialogue on the Assessment and Convergence of RES Policy in EU Member States - Final Report: IEE DiaCore Contract N°: IEE/12/833/SI2.645735 : Project Acronym: DIA-CORE
- Author
-
Boie, Inga, Breitschopf, B., Held, A., Ragwitz, Mario, Steinhilber, S., Resch, G., Welisch, M., C., Zehetner, Ortner, A., Busch, S., Liebmann, L., Totschnig, G., Noothout, P.M., de Jager, D., Tesniere, L., Van Rooijen, S., Karypidis, N., Bruckmann, R., Jirous, F., Psarras, J., Doukas, Haris, Angelopoulos, D., Genoese, F., Behrens, A., Dimitrova, A., Alessi, M., Drabik, E., Konstantinaviciute, I., Bobinaite, V., Miskinis, V., Tarvydas, D., Grau, T., Neuhoff, K., May, N., Hoefnagels, Ric, Junginger, H.M., Stütz, R., Steinbäcker, S., Boie, Inga, Breitschopf, B., Held, A., Ragwitz, Mario, Steinhilber, S., Resch, G., Welisch, M., C., Zehetner, Ortner, A., Busch, S., Liebmann, L., Totschnig, G., Noothout, P.M., de Jager, D., Tesniere, L., Van Rooijen, S., Karypidis, N., Bruckmann, R., Jirous, F., Psarras, J., Doukas, Haris, Angelopoulos, D., Genoese, F., Behrens, A., Dimitrova, A., Alessi, M., Drabik, E., Konstantinaviciute, I., Bobinaite, V., Miskinis, V., Tarvydas, D., Grau, T., Neuhoff, K., May, N., Hoefnagels, Ric, Junginger, H.M., Stütz, R., and Steinbäcker, S.
- Published
- 2016
16. Policy Dialogue on the Assessment and Convergence of RES Policy in EU Member States - Final Report: IEE DiaCore Contract N°: IEE/12/833/SI2.645735 : Project Acronym: DIA-CORE
- Author
-
Energy and Resources, Biobased Economy, Boie, Inga, Breitschopf, B., Held, A., Ragwitz, Mario, Steinhilber, S., Resch, G., Welisch, M., C., Zehetner, Ortner, A., Busch, S., Liebmann, L., Totschnig, G., Noothout, P.M., de Jager, D., Tesniere, L., Van Rooijen, S., Karypidis, N., Bruckmann, R., Jirous, F., Psarras, J., Doukas, Haris, Angelopoulos, D., Genoese, F., Behrens, A., Dimitrova, A., Alessi, M., Drabik, E., Konstantinaviciute, I., Bobinaite, V., Miskinis, V., Tarvydas, D., Grau, T., Neuhoff, K., May, N., Hoefnagels, Ric, Junginger, H.M., Stütz, R., Steinbäcker, S., Energy and Resources, Biobased Economy, Boie, Inga, Breitschopf, B., Held, A., Ragwitz, Mario, Steinhilber, S., Resch, G., Welisch, M., C., Zehetner, Ortner, A., Busch, S., Liebmann, L., Totschnig, G., Noothout, P.M., de Jager, D., Tesniere, L., Van Rooijen, S., Karypidis, N., Bruckmann, R., Jirous, F., Psarras, J., Doukas, Haris, Angelopoulos, D., Genoese, F., Behrens, A., Dimitrova, A., Alessi, M., Drabik, E., Konstantinaviciute, I., Bobinaite, V., Miskinis, V., Tarvydas, D., Grau, T., Neuhoff, K., May, N., Hoefnagels, Ric, Junginger, H.M., Stütz, R., and Steinbäcker, S.
- Published
- 2016
17. Comparative genomics analysis of streptococcus tigurinus strains identifies genetic elements specifically and uniquely present in highly virulent strains
- Author
-
Diene, S M, François, P, Zbinden, A, Entenza, J M, Resch, G, Diene, S M, François, P, Zbinden, A, Entenza, J M, and Resch, G
- Abstract
Streptococcus tigurinus is responsible for severe invasive infections such as infective endocarditis, spondylodiscitis and meningitis. As described, S. tigurinus isolates AZ_3aT and AZ_14 were highly virulent (HV phenotype) in an experimental model of infective endocarditis and showed enhanced adherence and invasion of human endothelial cells when compared to low virulent S. tigurinus isolate AZ_8 (LV phenotype). Here, we sought whether genetic determinants could explain the higher virulence of AZ_3aT and AZ_14 isolates. Several genetic determinants specific to the HV strains were identified through extensive comparative genomics amongst which some were thought to be highly relevant for the observed HV phenotype. These included i) an iron uptake and metabolism operon, ii) an ascorbate assimilation operon, iii) a newly acquired PI-2-like pilus islets described for the first time in S. tigurinus, iv) a hyaluronate metabolism operon, v) an Entner-Doudoroff pathway of carbohydrates metabolism, and vi) an alternate pathways for indole biosynthesis. We believe that the identified genomic features could largely explain the phenotype of high infectivity of the two HV S. tigurinus strains. Indeed, these features include determinants that could be involved at different stages of the disease such as survival of S. tigurinus in blood (iron uptake and ascorbate metabolism operons), initial attachment of bacterial pathogen to the damaged cardiac tissue and/or vegetation that formed on site (PI-2-like pilus islets), tissue invasion (hyaluronate operon and Entner-Doudoroff pathway) and regulation of pathogenicity (indole biosynthesis pathway).
- Published
- 2016
18. Human Mozdok leptospirosis first diagnosed by serum agglutinin-absorption tests in the Slovak Republic.
- Author
-
Bakoss, P., Awad-Masalmeh, M., Resch, G., Jareková, J., Stanko, M., and Perželová, J.
- Published
- 2018
19. Mixed reality alters motor planning and control.
- Author
-
Wang XM, Nitsche M, Resch G, Mazalek A, and Welsh TN
- Abstract
Compared to physical unmediated reality (UR), mixed reality technologies, such as Virtual (VR) and Augmented (AR) Reality, entail perturbations across multiple sensory modalities (visual, haptic, etc.) that could alter how actors move within the different environments. Because of the mediated nature, goal-directed movements in VR and AR may rely on planning and control processes that are different from movements in UR, resulting in less efficient motor control. The current study involved participants performing manual pointing movements on Müller-Lyer illusion stimuli to examine the relative contributions of movement planning and online control in UR, VR, and AR. Compared to UR, movements in VR were slower but were equally variable with a comparable level of online control, whereas movements in AR showed comparable speed but exhibited higher variability and less online control. Further, movements in VR and AR demonstrated a greater illusory effect in endpoint accuracy relative to UR. These findings suggested that participants in VR adopted an active compensation strategy to overcome the impact of less efficient online control, whereas participants in AR did not. The findings that movement planning and execution in VR and AR are fundamentally different from those in UR provide valuable insights into the potential neural systems engaged during movements in different realities., Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest to declare that are relevant to the content of this article., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
20. Author Correction: Prolonged exposure to mixed reality alters task performance in the unmediated environment.
- Author
-
Wang XM, Southwick D, Robinson I, Nitsche M, Resch G, Mazalek A, and Welsh TN
- Published
- 2024
- Full Text
- View/download PDF
21. Prolonged exposure to mixed reality alters task performance in the unmediated environment.
- Author
-
Wang XM, Southwick D, Robinson I, Nitsche M, Resch G, Mazalek A, and Welsh TN
- Subjects
- Humans, Male, Female, Adult, Young Adult, Augmented Reality, Movement physiology, Virtual Reality, Psychomotor Performance physiology, Task Performance and Analysis
- Abstract
The popularity of mixed reality (MR) technologies, including virtual (VR) and augmented (AR) reality, have advanced many training and skill development applications. If successful, these technologies could be valuable for high-impact professional training, like medical operations or sports, where the physical resources could be limited or inaccessible. Despite MR's potential, it is still unclear whether repeatedly performing a task in MR would affect performance in the same or related tasks in the physical environment. To investigate this issue, participants executed a series of visually-guided manual pointing movements in the physical world before and after spending one hour in VR or AR performing similar movements. Results showed that, due to the MR headsets' intrinsic perceptual geometry, movements executed in VR were shorter and movements executed in AR were longer than the veridical Euclidean distance. Crucially, the sensorimotor bias in MR conditions also manifested in the subsequent post-test pointing task; participants transferring from VR initially undershoot whereas those from AR overshoot the target in the physical environment. These findings call for careful consideration of MR-based training because the exposure to MR may perturb the sensorimotor processes in the physical environment and negatively impact performance accuracy and transfer of training from MR to UR., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
22. Optical Trapping and Fast Discrimination of Label-Free Bacteriophages at the Single Virion Level.
- Author
-
Villa N, Tartari E, Glicenstein S, de Villiers de la Noue H, Picard E, Marcoux PR, Zelsmann M, Resch G, Hadji E, and Houdré R
- Subjects
- Bacteriophages physiology, Virion, Optical Tweezers
- Abstract
There is a recent resurgence of interest in phage therapy (the therapeutic use of bacterial viruses) as an approach to eliminating difficult-to-treat infections. However, existing approaches for therapeutic phage selection and virulence testing are time-consuming, host-dependent, and facing reproducibility issues. Here, this study presents an innovative approach wherein integrated resonant photonic crystal (PhC) cavities in silicon are used as optical nanotweezers for probing and manipulating single bacteria and single virions with low optical power. This study demonstrates that these nanocavities differentiate between a bacterium and a phage without labeling or specific surface bioreceptors. Furthermore, by tailoring the spatial extent of the resonant optical mode in the low-index medium, phage distinction across phenotypically distinct phage families is demonstrated. The work paves the road to the implementation of optical nanotweezers in phage therapy protocols., (© 2024 The Authors. Small published by Wiley‐VCH GmbH.)
- Published
- 2024
- Full Text
- View/download PDF
23. The MAPK homolog, Smk1, promotes assembly of the glucan layer of the spore wall in S. cerevisiae.
- Author
-
Lee-Soety JY, Resch G, Rimal A, Johnson ES, Benway J, and Winter E
- Subjects
- Glucosyltransferases genetics, Glucosyltransferases metabolism, Membrane Proteins, Cell Wall metabolism, Cell Wall genetics, Glucans metabolism, Mitogen-Activated Protein Kinases metabolism, Mitogen-Activated Protein Kinases genetics, Saccharomyces cerevisiae genetics, Saccharomyces cerevisiae metabolism, Saccharomyces cerevisiae enzymology, Saccharomyces cerevisiae Proteins genetics, Saccharomyces cerevisiae Proteins metabolism, Spores, Fungal genetics, Spores, Fungal growth & development, Spores, Fungal metabolism
- Abstract
Smk1 is a MAPK homolog in the yeast Saccharomyces cerevisiae that controls the postmeiotic program of spore wall assembly. During this program, haploid cells are surrounded by a layer of mannan and then a layer of glucan. These inner layers of the spore wall resemble the vegetative cell wall. Next, the outer layers consisting of chitin/chitosan and then dityrosine are assembled. The outer layers are spore-specific and provide protection against environmental stressors. Smk1 is required for the proper assembly of spore walls. However, the protective properties of the outer layers have limited our understanding of how Smk1 controls this morphogenetic program. Mutants lacking the chitin deacetylases, Cda1 and Cda2, form spores that lack the outer layers of the spore wall. In this study, cda1,2∆ cells were used to demonstrate that Smk1 promotes deposition of the glucan layer of the spore wall through the partially redundant glucan synthases Gsc2 and Fks3. Although Gsc2 is localized to sites of spore wall assembly in the wild type, it is mislocalized in the mother cell cytoplasm in the smk1∆ mutant. These findings suggest that Smk1 controls assembly of the spore wall by regulating the localization of Gsc2 during sporogenesis., (© 2024 The Author(s). Yeast published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
24. Editorial: Standards in personalized phage therapy: from phage collection to phage production.
- Author
-
Kiljunen S and Resch G
- Subjects
- Anti-Bacterial Agents, Bacteriophages genetics, Phage Therapy
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
- Published
- 2024
- Full Text
- View/download PDF
25. The geometry of the vergence-accommodation conflict in mixed reality systems.
- Author
-
Wang XM, Southwick D, Robinson I, Nitsche M, Resch G, Mazalek A, and Welsh TN
- Abstract
Mixed reality technologies, such as virtual (VR) and augmented (AR) reality, present promising opportunities to advance education and professional training due to their adaptability to diverse contexts. Distortions in the perceived distance in such mediated conditions, however, are well documented and have imposed nontrivial challenges that complicate and limit transferring task performance in a virtual setting to the unmediated reality (UR). One potential source of the distance distortion is the vergence-accommodation conflict-the discrepancy between the depth specified by the eyes' accommodative state and the angle at which the eyes converge to fixate on a target. The present study involved the use of a manual pointing task in UR, VR, and AR to quantify the magnitude of the potential depth distortion in each modality. Conceptualizing the effect of vergence-accommodation offset as a constant offset to the vergence angle, a model was developed based on the stereoscopic viewing geometry. Different versions of the model were used to fit and predict the behavioral data for all modalities. Results confirmed the validity of the conceptualization of vergence-accommodation as a device-specific vergence offset, which predicted up to 66% of the variance in the data. The fitted parameters indicate that, due to the vergence-accommodation conflict, participants' vergence angle was driven outwards by approximately 0.2°, which disrupted the stereoscopic viewing geometry and produced distance distortion in VR and AR. The implications of this finding are discussed in the context of developing virtual environments that minimize the effect of depth distortion., Competing Interests: Conflict of interestThe authors have no conflicts of interest to declare that are relevant to the content of this article., (© The Author(s) 2024.)
- Published
- 2024
- Full Text
- View/download PDF
26. From microbiome composition to functional engineering, one step at a time.
- Author
-
Burz SD, Causevic S, Dal Co A, Dmitrijeva M, Engel P, Garrido-Sanz D, Greub G, Hapfelmeier S, Hardt W-D, Hatzimanikatis V, Heiman CM, Herzog MK-M, Hockenberry A, Keel C, Keppler A, Lee S-J, Luneau J, Malfertheiner L, Mitri S, Ngyuen B, Oftadeh O, Pacheco AR, Peaudecerf F, Resch G, Ruscheweyh H-J, Sahin A, Sanders IR, Slack E, Sunagawa S, Tackmann J, Tecon R, Ugolini GS, Vacheron J, van der Meer JR, Vayena E, Vonaesch P, and Vorholt JA
- Subjects
- Humans, Dysbiosis, Microbiota genetics
- Abstract
SUMMARYCommunities of microorganisms (microbiota) are present in all habitats on Earth and are relevant for agriculture, health, and climate. Deciphering the mechanisms that determine microbiota dynamics and functioning within the context of their respective environments or hosts (the microbiomes) is crucially important. However, the sheer taxonomic, metabolic, functional, and spatial complexity of most microbiomes poses substantial challenges to advancing our knowledge of these mechanisms. While nucleic acid sequencing technologies can chart microbiota composition with high precision, we mostly lack information about the functional roles and interactions of each strain present in a given microbiome. This limits our ability to predict microbiome function in natural habitats and, in the case of dysfunction or dysbiosis, to redirect microbiomes onto stable paths. Here, we will discuss a systematic approach (dubbed the N + 1/N-1 concept) to enable step-by-step dissection of microbiome assembly and functioning, as well as intervention procedures to introduce or eliminate one particular microbial strain at a time. The N+1/N-1 concept is informed by natural invasion events and selects culturable, genetically accessible microbes with well-annotated genomes to chart their proliferation or decline within defined synthetic and/or complex natural microbiota. This approach enables harnessing classical microbiological and diversity approaches, as well as omics tools and mathematical modeling to decipher the mechanisms underlying N+1/N-1 microbiota outcomes. Application of this concept further provides stepping stones and benchmarks for microbiome structure and function analyses and more complex microbiome intervention strategies., Competing Interests: The authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
27. Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid.
- Author
-
Mutti M, Moreno DS, Restrepo-Córdoba M, Visram Z, Resch G, and Corsini L
- Subjects
- Humans, Animals, Mice, Tissue Plasminogen Activator, Synovial Fluid, Staphylococcus Phages physiology, Anti-Bacterial Agents, Staphylococcus aureus physiology, Staphylococcal Infections therapy, Staphylococcal Infections microbiology
- Abstract
S. aureus is a pathogen that frequently causes severe morbidity and phage therapy is being discussed as an alternative to antibiotics for the treatment of S. aureus infections. In this in vitro and animal study, we demonstrated that the activity of anti-staphylococcal phages is severely impaired in 0.5% plasma or synovial fluid. Despite phage replication in these matrices, lysis of the bacteria was slower than phage propagation, and no reduction of the bacterial population was observed. The inhibition of the phages associated with a reduction in phage adsorption, quantified to 99% at 10% plasma. S. aureus is known to bind multiple coagulation factors, resulting in the formation of aggregates and blood clots that might protect the bacterium from the phages. Here, we show that purified fibrinogen at a sub-physiological concentration of 0.4 mg/ml is sufficient to impair phage activity. In contrast, dissolution of the clots by tissue plasminogen activator (tPA) partially restored phage activity. Consistent with these in vitro findings, phage treatment did not reduce bacterial burdens in a neutropenic mouse S. aureus thigh infection model. In summary, phage treatment of S. aureus infections inside the body may be fundamentally challenging, and more investigation is needed prior to proceeding to in-human trials., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
28. SECURES-Met: A European meteorological data set suitable for electricity modelling applications.
- Author
-
Formayer H, Nadeem I, Leidinger D, Maier P, Schöniger F, Suna D, Resch G, Totschnig G, and Lehner F
- Abstract
The modelling of electricity production and demand requires highly specific and comprehensive meteorological data. One challenge is the high temporal frequency as electricity production and demand modelling typically is done with hourly data. On the other side the European electricity market is highly connected, so that a pure country-based modelling is not expedient and at least the whole European Union (EU) area has to be considered. Additionally, the spatial resolution of the data set must be able to represent the thermal conditions, which requires high spatial resolution at least in mountainous regions. All these requirements lead to huge data amounts for historic observations and even more for climate change projections for the whole 21
st century. Thus, we have developed the aggregated European wide climate data set SECURES-Met that has a temporal resolution of one hour, covers the whole EU area and other selected European countries, has a reasonable size but considers the high spatial variability., (© 2023. Springer Nature Limited.)- Published
- 2023
- Full Text
- View/download PDF
29. Author Correction: Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa.
- Author
-
Köhler T, Luscher A, Falconnet L, Resch G, McBride R, Mai QA, Simonin JL, Chanson M, Maco B, Galiotto R, Riat A, Civic N, Docquier M, McCallin S, Chan B, and van Delden C
- Published
- 2023
- Full Text
- View/download PDF
30. Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa.
- Author
-
Köhler T, Luscher A, Falconnet L, Resch G, McBride R, Mai QA, Simonin JL, Chanson M, Maco B, Galiotto R, Riat A, Civic N, Docquier M, McCallin S, Chan B, and van Delden C
- Subjects
- Male, Humans, Pseudomonas aeruginosa, Lung, Drug Resistance, Multiple, Bacterial, Persistent Infection, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Bacteriophages genetics, Pneumonia, Pseudomonas Infections microbiology
- Abstract
Bacteriophage therapy has been suggested as an alternative or complementary strategy for the treatment of multidrug resistant (MDR) bacterial infections. Here, we report the favourable clinical evolution of a 41-year-old male patient with a Kartagener syndrome complicated by a life-threatening chronic MDR Pseudomonas aeruginosa infection, who is treated successfully with iterative aerosolized phage treatments specifically directed against the patient's isolate. We follow the longitudinal evolution of both phage and bacterial loads during and after phage administration in respiratory samples. Phage titres in consecutive sputum samples indicate in patient phage replication. Phenotypic analysis and whole genome sequencing of sequential bacterial isolates reveals a clonal, but phenotypically diverse population of hypermutator strains. The MDR phenotype in the collected isolates is multifactorial and mainly due to spontaneous chromosomal mutations. All isolates recovered after phage treatment remain phage susceptible. These results demonstrate that clinically significant improvement is achievable by personalised phage therapy even in the absence of complete eradication of P. aeruginosa lung colonization., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
31. [Phage therapy for respiratory infections].
- Author
-
Mitropoulou G, Gijs PJ, Koutsokera A, Sauty A, Blanchon S, Csajka C, Brunet JF, Resch G, Guery B, and Von Garnier C
- Subjects
- Humans, Drug Resistance, Microbial, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents pharmacology, Phage Therapy, Bacterial Infections therapy, Bacterial Infections microbiology, Bacteriophages, Respiratory Tract Infections therapy
- Abstract
The crisis of antibiotic resistance represents a global public health challenge, affecting particularly patients with respiratory infections. The use of (bacterio)phages for the treatment of bacterial infections (phage therapy) seems safe but its effectiveness has not yet been proven by controlled clinical trials. Nevertheless, phage therapy is regaining interest, encouraged by published cases treated successfully with personalized phage combinations as well as significant advances at a preclinical level. Standardized approaches in phage production and treatment administration, as well as future translational studies, are needed to improve our understanding and explore the potential of phage therapy., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
- Published
- 2022
- Full Text
- View/download PDF
32. Identification and Characterization of Erwinia Phage IT22: A New Bacteriophage-Based Biocontrol against Erwinia amylovora .
- Author
-
Sabri M, El Handi K, Valentini F, De Stradis A, Achbani EH, Benkirane R, Resch G, and Elbeaino T
- Subjects
- Plant Diseases prevention & control, Plant Diseases microbiology, Myoviridae genetics, Erwinia amylovora genetics, Bacteriophages genetics, Malus
- Abstract
Erwinia amylovora is a quarantine phytopathogenic bacterium that is the causal agent of fire blight, a destructive disease responsible for killing millions of fruit-bearing plants worldwide, including apple, pear, quince, and raspberry. Efficient and sustainable control strategies for this serious bacterial disease are still lacking, and traditional methods are limited to the use of antibiotics and some basic agricultural practices. This study aimed to contribute to the development of a sustainable control strategy through the identification, characterization, and application of bacteriophages (phages) able to control fire blight on pears. Phages isolated from wastewater collected in the Apulia region (southern Italy) were characterized and evaluated as antibacterial agents to treat experimental fire blight caused by E. amylovora . Transmission electron microscopy (TEM) conducted on purified phages (named EP-IT22 for Erwinia phage IT22) showed particles with icosahedral heads of ca. 90 ± 5 nm in length and long contractile tails of 100 ± 10 nm, typical of the Myoviridae family. Whole genome sequencing (WGS), assembly, and analysis of the phage DNA generated a single contig of 174.346 bp representing a complete circular genome composed of 310 open reading frames (ORFs). EP-IT22 was found to be 98.48% identical to the Straboviridae Erwinia phage Cronus (EPC) (GenBank Acc. n° NC_055743) at the nucleotide level. EP-IT22 was found to be resistant to high temperatures (up to 60 °C) and pH values between 4 and 11, and was able to accomplish a complete lytic cycle within one hour. Furthermore, the viability-qPCR and turbidity assays showed that EP-IT22 (MOI = 1) lysed 94% of E. amylovora cells in 20 h. The antibacterial activity of EP-IT22 in planta was evaluated in E. amylovora -inoculated pear plants that remained asymptomatic 40 days post inoculation, similarly to those treated with streptomycin sulphate. This is the first description of the morphological, biological, and molecular features of EP-IT22, highlighting its promising potential for biocontrol of E. amylovora against fire blight disease.
- Published
- 2022
- Full Text
- View/download PDF
33. Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations.
- Author
-
Mitropoulou G, Koutsokera A, Csajka C, Blanchon S, Sauty A, Brunet JF, von Garnier C, Resch G, and Guery B
- Subjects
- Bacteriophages, Humans, Legislation, Drug, Phage Therapy adverse effects, Pneumonia therapy
- Abstract
Lower respiratory tract infections lead to significant morbidity and mortality. They are increasingly caused by multidrug-resistant pathogens, notably in individuals with cystic fibrosis, hospital-acquired pneumonia and lung transplantation. The use of bacteriophages (phages) to treat bacterial infections is gaining growing attention, with numerous published cases of compassionate treatment over the last few years. Although the use of phages appears safe, the lack of standardisation, the significant heterogeneity of published studies and the paucity of robust efficacy data, alongside regulatory hurdles arising from the existing pharmaceutical legislation, are just some of the challenges phage therapy has to overcome. In this review, we discuss the lessons learned from recent clinical experiences of phage therapy for the treatment of pulmonary infections. We review the key aspects, opportunities and challenges of phage therapy regarding formulations and administration routes, interactions with antibiotics and the immune system, and phage resistance. Building upon the current knowledge base, future pre-clinical studies using emerging technologies and carefully designed clinical trials are expected to enhance our understanding and explore the therapeutic potential of phage therapy., Competing Interests: Conflict of interest: G. Mitropoulou has no financial relationships with organisations pertaining to this work Conflict of interest: A. Koutsokera has no financial relationships with organisations pertaining to this work. Conflict of interest: C. Csajka has no financial relationships with organisations pertaining to this work. Conflict of interest: S. Blanchon has no financial relationships with organisations pertaining to this work. Conflict of interest: A. Sauty has received payment/honoraria from Vertex (personal and on behalf of a non-profit foundation) for lectures and presentations. Conflict of interest: J-F. Brunet has no financial relationships with organisations pertaining to this work. Conflict of interest: C. von Garnier has no financial relationships with organisations pertaining to this work. Conflict of interest: G. Resch has no financial relationships with organisations pertaining to this work. Conflict of interest: B. Guery has received a grant from MSD (Merck & Co). He has received consulting fees from UPSA on behalf of the Lausanne University Hospital (CHUV), and participates at the Data Safety Monitoring Board of RHU Idioboriv., (Copyright ©The authors 2022.)
- Published
- 2022
- Full Text
- View/download PDF
34. Subtherapeutic Doses of Vancomycin Synergize with Bacteriophages for Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Infective Endocarditis.
- Author
-
Save J, Que YA, Entenza J, and Resch G
- Subjects
- Animals, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Microbial Sensitivity Tests, Rats, Vancomycin pharmacology, Vancomycin therapeutic use, Bacteriophages, Endocarditis drug therapy, Endocarditis, Bacterial drug therapy, Endocarditis, Bacterial microbiology, Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections drug therapy, Staphylococcal Infections microbiology
- Abstract
Background. Recurrent therapeutic failures reported for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infective endocarditis (IE) with vancomycin may be due to poor bactericidal activity. Alternative antibacterial approaches using bacteriophages may overcome this limitation. Objectives. An experimental rat model of MRSA IE (EE) was used to examine the efficacy of vancomycin combined with a 1:1 bacteriophage (phage) cocktail composed of Herelleviridae vB_SauH_2002 and Routreeviridae 66. Methods. Six hours after inoculation with ca. 5 log10 colony forming units (CFU) of MRSA strain AW7, animals were treated with either: (i) saline, (ii) an equimolar two-phage cocktail (bolus of 1 mL followed by a 0.3 mL/h continuous infusion of 10 log10 plaque forming units (PFU)/mL phage suspension), (iii) vancomycin (at a dose mimicking the kinetics in humans of 0.5 g b.i.d.), or (iv) a combination of both. Bacterial loads in vegetations, and phage loads in vegetations, liver, kidney, spleen, and blood, were measured outcomes. Results. Phage cocktail alone was unable to control the growth of strain AW7 in cardiac vegetations. However, when combined with subtherapeutic doses of vancomycin, a statistically significant decrease of ∆4.05 ± 0.94 log10 CFU/g at 24 h compared to placebo was detected (p < 0.001). The administration of vancomycin was found to significantly impact on the local concentrations of phages in the vegetations and in the organs examined. Conclusions. Lytic bacteriophages as an adjunct treatment to the standard of care antibiotics could potentially improve the management of MRSA IE. Further studies are needed to investigate the impact of antibiotics on phage replication in vivo.
- Published
- 2022
- Full Text
- View/download PDF
35. Benefits of Aerosolized Phages for the Treatment of Pneumonia Due to Methicillin-Resistant Staphylococcus aureus: An Experimental Study in Rats.
- Author
-
Prazak J, Valente LG, Iten M, Federer L, Grandgirard D, Soto S, Resch G, Leib SL, Jakob SM, Haenggi M, Cameron DR, and Que YA
- Subjects
- Animals, Linezolid therapeutic use, Rats, Bacteriophages, Methicillin-Resistant Staphylococcus aureus, Pneumonia, Staphylococcal microbiology, Pneumonia, Ventilator-Associated drug therapy
- Abstract
Background: The optimal method for delivering phages in the context of ventilator-associated pneumonia (VAP) is unknown. In the current study, we assessed the utility of aerosolized phages (aerophages) for experimental methicillin-resistant Staphylococcus aureus (MRSA) pneumonia., Methods: Rats were ventilated for 4 hours before induction of pneumonia. Animals received one of the following: (1) aerophages; (2) intravenous (IV) phages; (3) a combination of IV and aerophages; (4) IV linezolid; or (5) a combination of IV linezolid and aerophages. Phages were administered at 2, 12, 24, 48, and 72 hours, and linezolid was administered at 2, 12, 24, 36, 48, 60, and 72 hours. The primary outcome was survival at 96 hours. Secondary outcomes were bacterial and phage counts in tissues and histopathological scoring of the lungs., Results: Aerophages and IV phages each rescued 50% of animals from severe MRSA pneumonia (P < .01 compared with placebo controls). The combination of aerophages and IV phages rescued 91% of animals, which was higher than either monotherapy (P < .05). Standard-of-care antibiotic linezolid rescued 38% of animals. However, linezolid and aerophages did not synergize in this setting (55% survival)., Conclusions: Aerosolized phage therapy showed potential for the treatment of MRSA pneumonia in an experimental animal model and warrants further investigation for application in humans., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2022
- Full Text
- View/download PDF
36. Bacteriophages Combined With Subtherapeutic Doses of Flucloxacillin Act Synergistically Against Staphylococcus aureus Experimental Infective Endocarditis.
- Author
-
Save J, Que YA, Entenza JM, Kolenda C, Laurent F, and Resch G
- Subjects
- Animals, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Floxacillin pharmacology, Floxacillin therapeutic use, Rats, Staphylococcus aureus physiology, Bacteriophages physiology, Endocarditis microbiology, Endocarditis, Bacterial therapy, Staphylococcal Infections therapy
- Abstract
Background The potential of phage therapy for the treatment of endovascular Staphylococcus aureus infections remains to be evaluated. Methods and Results The efficacy of a phage cocktail combining Herelleviridae phage vB_SauH_2002 and Podoviriae phage 66 was evaluated against a methicillin-sensitive S. aureus strain in vitro and in vivo in a rodent model of experimental endocarditis. Six hours after bacterial challenge, animals were treated with (1) the phage cocktail. (2) subtherapeutic flucloxacillin dosage, (3) combination of the phage cocktail and flucloxacillin, or (4) saline. Bacterial loads in cardiac vegetations at 30 hours were the primary outcome. Secondary outcomes were phage loads at 30 hours in cardiac vegetations, blood, spleen, liver, and kidneys. We evaluated phage resistance 30 hours post infection in vegetations of rats under combination treatment. In vitro, phages synergized against S. aureus planktonic cells and the cocktail synergized with flucloxacillin to eradicated biofilms. In infected animals, the phage cocktail achieved bacteriostatic effect. The addition of low-dose flucloxacillin elevated bacterial suppression (∆ of -5.25 log
10 colony forming unit/g [CFU/g] versus treatment onset, P <0.0001) and synergism was confirmed (∆ of -2.15 log10 CFU/g versus low-dose flucloxacillin alone, P <0.01). Importantly, 9/12 rats given the combination treatment had sterile vegetations at 30 hours. In vivo phage replication was partially suppressed by the antibiotic and selection of resistance to the Podoviridae component of the phage cocktail occurred. Plasma-mediated inhibition of phage killing activity was observed in vitro. Conclusions Combining phages with a low-dose standard of care antibiotic represents a promising strategy for the treatment of S. aureus infective endocarditis.- Published
- 2022
- Full Text
- View/download PDF
37. Recent progress toward the implementation of phage therapy in Western medicine.
- Author
-
Pirnay JP, Ferry T, and Resch G
- Subjects
- Anti-Bacterial Agents therapeutic use, Humans, Bacterial Infections therapy, Bacteriophages, Phage Therapy
- Abstract
Like the sword of Damocles, the threat of a post-antibiotic era is hanging over humanity's head. The scientific and medical community is thus reconsidering bacteriophage therapy (BT) as a partial but realistic solution for treatment of difficult-to-eradicate bacterial infections. Here, we summarize the latest developments in clinical BT applications, with a focus on developments in the following areas: (i) pharmacology of bacteriophages of major clinical importance and their synergy with antibiotics; (ii) production of therapeutic phages; and (iii) clinical trials, case studies and case reports in the field. We address regulatory concerns, which are of paramount importance insofar as they dictate the conduct of clinical trials, which are needed for broader BT application. The increasing amount of new available data confirms the particularities of BT as being innovative and highly personalized. The current circumstances suggest that the immediate future of BT may be advanced within the framework of national BT centers in collaboration with competent authorities, which are urged to adopt incisive initiatives originally launched by some national regulatory authorities., (© The Author(s) 2021. Published by Oxford University Press on behalf of FEMS. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
38. Unpuzzling Friunavirus-Host Interactions One Piece at a Time: Phage Recognizes Acinetobacter pittii via a New K38 Capsule Depolymerase.
- Author
-
Domingues R, Barbosa A, Santos SB, Pires DP, Save J, Resch G, Azeredo J, and Oliveira H
- Abstract
Acinetobacter pittii is a species that belong to the Acinetobacter calcoaceticus-baumannii complex, increasingly recognized as major nosocomial bacterial pathogens, often associated with multiple drug-resistances. The capsule surrounding the bacteria represents a main virulence factor, helping cells avoid phage predation and host immunity. Accordingly, a better understanding of the phage infection mechanisms is required to efficiently develop phage therapy against Acinetobacter of different capsular types. Here, we report the isolation of the novel A. pittii -infecting Fri1-like phage vB_Api_3043-K38 (3043-K38) of the Podoviridae morphotype, from sewage samples. Its 41,580 bp linear double-stranded DNA genome harbours 53 open reading frames and 302 bp of terminal repeats. We show that all studied Acinetobacter Fri1-like viruses have highly similar genomes, which differentiate only at the genes coding for tailspike, likely to adapt to different host receptors. The isolated phage 3043-K38 specifically recognizes an untapped Acinetobacter K38 capsule type via a novel tailspike with K38 depolymerase activity. The recombinant K38 depolymerase region of the tailspike (center-end region) forms a thermostable trimer, and quickly degrades capsules. When the K38 depolymerase is applied to the cells, it makes them resistant to phage predation. Interestingly, while K38 depolymerase treatments do not synergize with antibiotics, it makes bacterial cells highly susceptible to the host serum complement. In summary, we characterized a novel phage-encoded K38 depolymerase, which not only advances our understanding of phage-host interactions, but could also be further explored as a new antibacterial agent against drug-resistant Acinetobacter .
- Published
- 2021
- Full Text
- View/download PDF
39. Unsupervised hyperspectral stimulated Raman microscopy image enhancement: denoising and segmentation via one-shot deep learning.
- Author
-
Abdolghader P, Ridsdale A, Grammatikopoulos T, Resch G, Légaré F, Stolow A, Pegoraro AF, and Tamblyn I
- Abstract
Hyperspectral stimulated Raman scattering (SRS) microscopy is a label-free technique for biomedical and mineralogical imaging which can suffer from low signal-to-noise ratios. Here we demonstrate the use of an unsupervised deep learning neural network for rapid and automatic denoising of SRS images: UHRED (Unsupervised Hyperspectral Resolution Enhancement and Denoising). UHRED is capable of "one-shot" learning; only one hyperspectral image is needed, with no requirements for training on previously labelled datasets or images. Furthermore, by applying a k-means clustering algorithm to the processed data, we demonstrate automatic, unsupervised image segmentation, yielding, without prior knowledge of the sample, intuitive chemical species maps, as shown here for a lithium ore sample.
- Published
- 2021
- Full Text
- View/download PDF
40. Complete Genome Sequence of Pseudomonas Phage Zikora.
- Author
-
Ezemokwe CG, Agwom FM, Okoliegbe I, Okonkwo FO, Ngene AC, Gimba N, Morenikeji OR, Egwuenu A, Okonkwo CH, Aguiyi JC, Nnadi NE, and Resch G
- Abstract
Pseudomonas aeruginosa is a major pathogen in humans and other animals, frequently harboring mechanisms of resistance to commonly used antimicrobials. Here, we describe the isolation of Pseudomonas bacteriophage Zikora. The full 65,837-bp genome was annotated and demonstrates similarity to Pbunavirus phages, making Zikora a new member of this genus of the Myoviridae family.
- Published
- 2021
- Full Text
- View/download PDF
41. ε 2 -Phages Are Naturally Bred and Have a Vastly Improved Host Range in Staphylococcus aureus over Wild Type Phages.
- Author
-
Sáez Moreno D, Visram Z, Mutti M, Restrepo-Córdoba M, Hartmann S, Kremers AI, Tišáková L, Schertler S, Wittmann J, Kalali B, Monecke S, Ehricht R, Resch G, and Corsini L
- Abstract
Due to the rapid spread of antibiotic resistance, and the difficulties of treating biofilm-associated infections, alternative treatments for S. aureus infections are urgently needed. We tested the lytic activity of several wild type phages against a panel of 110 S. aureus strains (MRSA/MSSA) composed to reflect the prevalence of S. aureus clonal complexes in human infections. The plaquing host ranges (PHR) of the wild type phages were in the range of 51% to 60%. We also measured what we called the kinetic host range (KHR), i.e., the percentage of strains for which growth in suspension was suppressed for 24 h. The KHR of the wild type phages ranged from 2% to 49%, substantially lower than the PHRs. To improve the KHR and other key pharmaceutical properties, we bred the phages by mixing and propagating cocktails on a subset of S. aureus strains. These bred phages, which we termed evolution-squared (ε
2 ) phages, have broader KHRs up to 64% and increased virulence compared to the ancestors. The ε2 -phages with the broadest KHR have genomes intercrossed from up to three different ancestors. We composed a cocktail of three ε2 -phages with an overall KHR of 92% and PHR of 96% on 110 S. aureus strains and called it PM-399. PM-399 has a lower propensity to resistance formation than the standard of care antibiotics vancomycin, rifampicin, or their combination, and no resistance was observed in laboratory settings (detection limit: 1 cell in 1011 ). In summary, ε2 -phages and, in particular PM-399, are promising candidates for an alternative treatment of S. aureus infections.- Published
- 2021
- Full Text
- View/download PDF
42. Isolation and characterization of bacteriophages from the human skin microbiome that infect Staphylococcus epidermidis .
- Author
-
Valente LG, Pitton M, Fürholz M, Oberhaensli S, Bruggmann R, Leib SL, Jakob SM, Resch G, Que YA, and Cameron DR
- Abstract
Phage therapy might be a useful approach for the treatment of nosocomial infections; however, only few lytic phages suitable for this application are available for the opportunistic pathogen, Staphylococcus epidermidis . In the current study, we developed an efficient method to isolate bacteriophages present within the human skin microbiome, by using niche-specific S. epidermidis as the host for phage propagation. Staphylococcus epidermidis was identified on the forehead of 92% of human subjects tested. These isolates were then used to propagate phages present in the same skin sample. Plaques were observable on bacterial lawns in 46% of the cases where S. epidermidis was isolated. A total of eight phage genomes were genetically characterized, including the previously described phage 456. A total of six phage sequences were unique, and spanned each of the major staphylococcal phage families; Siphoviridae ( n = 3), Podoviridae ( n = 1) and Myoviridae ( n = 2). One of the myoviruses (vB_SepM_BE06) was identified on the skin of three different humans. Comparative analysis identified novel genes including a putative N-acetylmuramoyl-L-alanine amidase gene. The host-range of each unique phage was characterized using a panel of diverse staphylococcal strains ( n = 78). None of the newly isolated phages infected more than 52% of the S. epidermidis strains tested ( n = 44), and non- S. epidermidis strains where rarely infected, highlighting the narrow host-range of the phages. One of the phages (vB_SepM_BE04) was capable of killing staphylococcal cells within biofilms formed on polyurethane catheters. Uncovering a richer diversity of available phages will likely improve our understanding of S. epidermidis -phage interactions, which will be important for future therapy., Competing Interests: None declared., (© The Author(s) 2021. Published by Oxford University Press on behalf of FEMS.)
- Published
- 2021
- Full Text
- View/download PDF
43. Phage susceptibility testing and infectious titer determination through wide-field lensless monitoring of phage plaque growth.
- Author
-
Perlemoine P, Marcoux PR, Picard E, Hadji E, Zelsmann M, Mugnier G, Marchet A, Resch G, O'Connell L, and Lacot E
- Subjects
- Bacteria virology, Kinetics, Time Factors, Bacteriophages growth & development, Image Processing, Computer-Assisted, Lenses
- Abstract
The growing number of drug-resistant bacterial infections worldwide is driving renewed interest in phage therapy. Based on the use of a personalized cocktail composed of highly specific bacterial viruses, this therapy relies on a range of tests on agar media to determine the most active phage on a given bacterial target (phage susceptibility testing), or to isolate new lytic phages from an environmental sample (enrichment of phage banks). However, these culture-based techniques are still solely interpreted through direct visual detection of plaques. The main objective of this work is to investigate computer-assisted methods in order to ease and accelerate diagnosis in phage therapy but also to study phage plaque growth kinetics. For this purpose, we designed a custom wide-field lensless imaging device, which allows continuous monitoring over a very large area sensor (3.3 cm2). Here we report bacterial susceptibility to Staphylococcus aureus phage in 3 hr and estimation of infectious titer in 8 hr 20 min. These are much shorter time-to-results than the 12 to 24 hours traditionally needed, since naked eye observation and counting of phage plaques is still the most widely used technique for susceptibility testing prior to phage therapy. Moreover, the continuous monitoring of the samples enables the study of plaque growth kinetics, which enables a deeper understanding of the interaction between phage and bacteria. Finally, thanks to the 4.3 μm resolution, we detect phage-resistant bacterial microcolonies of Klebsiella pneumoniae inside the boundaries of phage plaques and thus show that our prototype is also a suitable device to track phage resistance. Lensless imaging is therefore an all-in-one method that could easily be implemented in cost-effective and compact devices in phage laboratories to help with phage therapy diagnosis., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
44. Engineered Phage Endolysin Eliminates Gardnerella Biofilm without Damaging Beneficial Bacteria in Bacterial Vaginosis Ex Vivo.
- Author
-
Landlinger C, Tisakova L, Oberbauer V, Schwebs T, Muhammad A, Latka A, Van Simaey L, Vaneechoutte M, Guschin A, Resch G, Swidsinski S, Swidsinski A, and Corsini L
- Abstract
Bacterial vaginosis is characterized by an imbalance of the vaginal microbiome and a characteristic biofilm formed on the vaginal epithelium, which is initiated and dominated by Gardnerella bacteria, and is frequently refractory to antibiotic treatment. We investigated endolysins of the type 1,4-beta-N-acetylmuramidase encoded on Gardnerella prophages as an alternative treatment. When recombinantly expressed, these proteins demonstrated strong bactericidal activity against four different Gardnerella species. By domain shuffling, we generated several engineered endolysins with 10-fold higher bactericidal activity than any wild-type enzyme. When tested against a panel of 20 Gardnerella strains, the most active endolysin, called PM-477, showed minimum inhibitory concentrations of 0.13-8 µg/mL. PM-477 had no effect on beneficial lactobacilli or other species of vaginal bacteria. Furthermore, the efficacy of PM-477 was tested by fluorescence in situ hybridization on vaginal samples of fifteen patients with either first time or recurring bacterial vaginosis. In thirteen cases, PM-477 killed the Gardnerella bacteria and physically dissolved the biofilms without affecting the remaining vaginal microbiome. The high selectivity and effectiveness in eliminating Gardnerella , both in cultures of isolated strains as well as in clinically derived samples of natural polymicrobial biofilms, makes PM-477 a promising alternative to antibiotics for the treatment of bacterial vaginosis, especially in patients with frequent recurrence., Competing Interests: Conflicts of interest have been declared by the following authors: CL, LT, VO are employees of PhagoMed Biopharma GmbH at the time of the study and LC holds shares in PhagoMed Biopharma GmbH and is the inventor on a patent application related to the work described here. The research of AS, AL, LVS, and MV has been supported financially by PhagoMed Biopharma GmbH.
- Published
- 2021
- Full Text
- View/download PDF
45. The multidomain architecture of a bacteriophage endolysin enables intramolecular synergism and regulation of bacterial lysis.
- Author
-
Oechslin F, Menzi C, Moreillon P, and Resch G
- Subjects
- Cell Wall, Protein Domains, Streptococcus virology, Bacteriolysis, Endopeptidases chemistry, Endopeptidases metabolism, N-Acetylmuramoyl-L-alanine Amidase metabolism, Peptidoglycan metabolism, Streptococcus growth & development, Streptococcus Phages enzymology
- Abstract
Endolysins are peptidoglycan hydrolases produced at the end of the bacteriophage (phage) replication cycle to lyse the host cell. Endolysins in Gram-positive phages come in a variety of multimodular forms that combine different catalytic and cell wall binding domains. However, the reason why phages adopt endolysins with such complex multidomain architecture is not well understood. In this study, we used the Streptococcus dysgalactiae phage endolysin PlySK1249 as a model to investigate the role of multidomain architecture in phage-induced bacterial lysis and lysis regulation. PlySK1249 consists of an amidase (Ami) domain that lyses bacterial cells, a nonbacteriolytic endopeptidase (CHAP) domain that acts as a dechaining enzyme, and a central LysM cell wall binding domain. We observed that the Ami and CHAP domains synergized for peptidoglycan digestion and bacteriolysis in the native enzyme or when expressed individually and reunified. The CHAP endopeptidase resolved complex polymers of stem-peptides to dimers and helped the Ami domain to digest peptidoglycan to completion. We also found that PlySK1249 was subject to proteolytic cleavage by host cell wall proteases both in vitro and after phage induction. Cleavage disconnected the different domains by hydrolyzing their linker regions, thus hindering their bacteriolytic cooperation and possibly modulating the lytic activity of the enzyme. PlySK1249 cleavage by cell-wall-associated proteases may represent another example of phage adaptation toward the use of existing bacterial regulation mechanism for their own advantage. In addition, understanding more thoroughly the multidomain interplay of PlySK1249 broadens our knowledge on the ideal architecture of therapeutic antibacterial endolysins., Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
46. Editorial: Manufacturing, Formulation and Delivery Issues for Phage Therapy to Become A Reality.
- Author
-
Malik DJ and Resch G
- Published
- 2020
- Full Text
- View/download PDF
47. Reusability of filtering facepiece respirators after decontamination through drying and germicidal UV irradiation.
- Author
-
Vernez D, Save J, Oppliger A, Concha-Lozano N, Hopf NB, Niculita-Hirzel H, Resch G, Michaud V, Dorange-Pattoret L, Charrière N, Batsungnoen K, and Suarez G
- Subjects
- Betacoronavirus, COVID-19, Coronavirus Infections prevention & control, Equipment Failure Analysis, Humans, Infection Control methods, Materials Testing, Pandemics prevention & control, Pneumonia, Viral prevention & control, SARS-CoV-2, Decontamination methods, Equipment Contamination prevention & control, Equipment Reuse, Respiratory Protective Devices, Ultraviolet Rays
- Abstract
Introduction: During pandemics, such as the SARS-CoV-2, filtering facepiece respirators plays an essential role in protecting healthcare personnel. The recycling of respirators is possible in case of critical shortage, but it raises the question of the effectiveness of decontamination as well as the performance of the reused respirators., Method: Disposable respirators were subjected to ultraviolet germicidal irradiation (UVGI) treatment at single or successive doses of 60 mJ/cm
2 after a short drying cycle (30 min, 70°C). The germicidal efficacy of this treatment was tested by spiking respirators with two staphylococcal bacteriophages (vB_HSa_2002 and P66 phages). The respirator performance was investigated by the following parameters: particle penetration (NaCl aerosol, 10-300 nm), scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry and mechanical tensile tests., Results: No viable phage particles were recovered from any of the respirators after decontamination (log reduction in virus titre >3), and no reduction in chemical or physical properties (SEM, particle penetrations <5%-6%) were observed. Increasing the UVGI dose 10-fold led to chemical alterations of the respirator filtration media (FTIR) but did not affect the physical properties (particle penetration), which was unaltered even at 3000 mJ/cm2 (50 cycles). When respirators had been used by healthcare workers and undergone decontamination, they had particle penetration significantly greater than never donned respirators., Conclusion: This decontamination procedure is an attractive method for respirators in case of shortages during a SARS pandemic. A successful implementation requires a careful design and particle penetration performance control tests over the successive reuse cycles., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2020
- Full Text
- View/download PDF
48. Combined Bacteriophage and Antibiotic Treatment Prevents Pseudomonas aeruginosa Infection of Wild Type and cftr - Epithelial Cells.
- Author
-
Luscher A, Simonin J, Falconnet L, Valot B, Hocquet D, Chanson M, Resch G, Köhler T, and van Delden C
- Abstract
With the increase of infections due to multidrug resistant bacterial pathogens and the shortage of antimicrobial molecules with novel targets, interest in bacteriophages as a therapeutic option has regained much attraction. Before the launch of future clinical trials, in vitro studies are required to better evaluate the efficacies and potential pitfalls of such therapies. Here we studied in an ex vivo human airway epithelial cell line model the efficacy of phage and ciprofloxacin alone and in combination to treat infection by Pseudomonas aeruginosa . The Calu-3 cell line and the isogenic CFTR knock down cell line ( cftr -) infected apically with P. aeruginosa strain PAO1 showed a progressive reduction in transepithelial resistance during 24 h. Administration at 6 h p.i. of single phage, phage cocktails or ciprofloxacin alone prevented epithelial layer destruction at 24 h p.i. Bacterial regrowth, due to phage resistant mutants harboring mutations in LPS synthesis genes, occurred thereafter both in vitro and ex vivo . However, co-administration of two phages combined with ciprofloxacin efficiently prevented PAO1 regrowth and maintained epithelial cell integrity at 72 p.i. The phage/ciprofloxacin treatment did not induce an inflammatory response in the tested cell lines as determined by nanoString
® gene expression analysis. We conclude that combination of phage and ciprofloxacin efficiently protects wild type and cftr - epithelial cells from infection by P. aeruginosa and emergence of phage resistant mutants without inducing an inflammatory response. Hence, phage-antibiotic combination should be a safe and promising anti-Pseudomonas therapy for future clinical trials potentially including cystic fibrosis patients., (Copyright © 2020 Luscher, Simonin, Falconnet, Valot, Hocquet, Chanson, Resch, Köhler and van Delden.)- Published
- 2020
- Full Text
- View/download PDF
49. Characterization and Lytic Activity of Isolated Escherichia coli Bacteriophages against Escherichia coli in vitro .
- Author
-
Rahimzadeh G, Resch G, Rezai MS, and Nemati Hevelaee E
- Abstract
Background: Escherichia coli ( E. coli ) is the most common cause of urinary tract infection (UTI) and typically treated with antibiotics. Unrestricted use of antibiotics may lead to the emergence of antibiotic-resistant bacteria. The present study aimed to isolate and characterize phages against E. coli from infected urine samples and to determine the lytic activity of phages against E. coli in vitro ., Methods: The present experimental study was conducted in the Laboratory of Bouali Sina Hospital (Sari, Iran) in May 2018. E. coli was identified from nine urine samples of patients with UTI using conventional microbiological methods. Bacteriophages were isolated from the infected urine specimens, and their lytic activity was determined using the spot test. The titer of the bacteriophages was measured using the double-layer agar technique. The morphology of the bacteriophages was revealed using transmission electron microscopy, and the latent time period and burst size were determined. Data were analyzed using the SPSS software package., Results: E. coli was isolated from nine infected urine samples. The lytic activity of bacteriophages against E. coli was determined using the spot test by observing the formation of inhibition zones. Transmission electron microscopy showed E. coli phages belonging to the Myoviridae family. The latent time period was 20 minutes with a burst size of 1,200 plaque-forming unit (PFU) per infected cell. The results of the double-layer agar assay showed that the titer of bacteriophages was 20×10
8 PFU/mL., Conclusion: The E. coli bacteriophage was isolated from infected urine samples and characterized, and their lytic activity against E. coli was determined in vitro ., (Copyright: © Iranian Journal of Medical Sciences.)- Published
- 2020
- Full Text
- View/download PDF
50. Efficacy of newly isolated and highly potent bacteriophages in a mouse model of extensively drug-resistant Acinetobacter baumannii bacteraemia.
- Author
-
Leshkasheli L, Kutateladze M, Balarjishvili N, Bolkvadze D, Save J, Oechslin F, Que YA, and Resch G
- Subjects
- Acinetobacter Infections microbiology, Acinetobacter baumannii pathogenicity, Animals, Anti-Bacterial Agents therapeutic use, Bacteremia microbiology, Bacteriophages isolation & purification, Bacteriophages physiology, Disease Models, Animal, Female, Injections, Intraperitoneal, Larva microbiology, Mice, Moths microbiology, Sewage virology, Acinetobacter Infections therapy, Bacteremia therapy, Drug Resistance, Multiple, Bacterial, Phage Therapy
- Abstract
Objectives: Bacteraemia can be caused by Acinetobacter baumannii (A. baumannii), with clinical manifestations ranging from transient bacteraemia to septic shock. Extensively drug-resistant A. baumannii (XDRAB) strains producing the New Delhi metallo-ß-lactamase, which confers resistance to all ß-lactams including carbapenems, have emerged. Infected patients suffer increased mortality, morbidity and length of hospitalisation. The lack of new antimicrobials has led to a renewed interest in phage therapy, the so-called forgotten cure. Accordingly, we tested new lytic bacteriophages in a Galleria mellonella and a mouse model of XDRAB-induced bacteraemia., Methods: Galleria mellonella were challenged with 5.10
5 CFU of the XDRAB strain FER. Phages vB_AbaM_3054 and vB_AbaM_3090 were administrated alone or in combination 30min after bacterial challenge. Saline and imipenem were injected as controls. Mice were intraperitoneally (i.p.) challenged with 6.107 CFU of A. baumannii FER. vB_AbaM_3054 and vB_AbaM_3090 were administrated i.p. alone or in combination 2h after bacterial challenge. Saline and imipenem were injected as controls. Larvae and mice survival were followed for 7 days and compared with Log-Rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon tests., Results: Phage-based treatments showed high efficacy in larvae (ca. 100% survival at 80h) and mice (ca. 100% survival at day 7) compared with the untreated controls (0% survival at 48h and 24h in larvae and mice, respectively)., Conclusions: The present data reporting efficacy of phage therapy in a mouse model of bacteraemia support the development of phage-based drugs to manage infection due to multi-drug resistant A. baumannii and particularly XDRAB., (Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.